Market Intelligence for L-type Calcium Channel Therapeutics: From Cardiovascular Blockade to CNS Precision Medicine and Subunit-Selective Modulation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CACNA1C ion channel drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | CACNA1C Full-Length Lentivirus – High-titer particles (>10^8 TU/mL) for stable cell line generation. Puromycin selection. Supports co-expression with accessory subunits (CACNB2, CACNA2D1). | View CACNA1C Products |
| Antigen | CACNA1C Extracellular Loop Domains – Recombinant fragments (Loop I-II, III-IV) expressed in HEK293. Sequence Verified. High Purity (>95%). Endotoxin <1EU/ug. | View CACNA1C Products |
| Benchmark Ab | Anti-CACNA1C (Cav1.2) Monoclonal Reference – Recombinant antibody for Western Blot, ICC, and Flow Cytometry validation. Sequence Verified. | View CACNA1C Products |
| Validator | CACNA1C siRNA Set – For knockdown verification and assay specificity controls. Sequence Verified. | View CACNA1C Products |
| Related Target | CACNA1D (Cav1.3) – Neuronal/Endocrine L-type channel. Critical off-target for CNS drugs; selectivity screening essential. | View CACNA1D Products |
| Related Target | CACNB2 (Beta-2 Subunit) – Chaperone for membrane trafficking and gating modulation. Required for functional CACNA1C expression. | View CACNB2 Products |
| Related Target | CACNA2D1 (Alpha2-Delta-1) – Accessory subunit and target of gabapentinoids. Functional partner in calcium channel complexes. | View CACNA2D1 Products |
| Related Target | RYR2 – Downstream calcium release channel in cardiac muscle; key for excitation-contraction coupling studies. | View RYR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-subunit Functional Expression | High-titer Lentivirus compatible with CACNB2/CACNA2D1 co-transduction; suitable for generating excitable cell lines with native gating properties. |
| State-Dependent Compound Screening | Stable HEK293 Cell Lines expressing full-length CACNA1C, suitable for Manual Patch-Clamp, Automated Patch-Clamp (APC), and FLIPR Calcium Flux assays. |
| CACNA1C vs CACNA1D Selectivity | Ortholog-Specific Cell Lines (Human, Cyno, Mouse) with sequence-verified ORFs to validate cross-species pharmacology. |
| Use-Dependent Block Liability | High-expression cell lines designed for high-frequency stimulation protocols to assess use-dependent inhibition. |
| Subfamily Counter Screening (Cav1.2 vs Cav1.3) | Comprehensive ion channel target panels and sequence-verified ORF delivery for precise counter-screening. |
| Lack of Reliable Controls | Recombinant positive control antibodies for flow cytometry and expression verification. |
| False Positives in Screening | Validated siRNA sets for target-specific knockdown verification in cell-based assays. |
Live CACNA1C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for CACNA1C (encoding the Cav1.2 α1 subunit) is undergoing a paradigm shift. Traditional dihydropyridine calcium channel blockers (CCBs) remain standard-of-care for hypertension and angina. Meanwhile, genome-wide association studies (GWAS) have firmly established CACNA1C as a premier risk gene for psychiatric disorders—including schizophrenia, bipolar disorder, and autism spectrum disorder. This has catalyzed a new wave of R&D focused on CNS-penetrant, state-dependent modulators that can selectively tune neuronal excitability without engendering cardiovascular liability. The next frontier involves precision therapeutics targeting specific channel conformations and splice variants, alongside gene therapy approaches for rare gain-of-function disorders such as Timothy Syndrome (e.g., G406R mutation). The critical bottleneck remains achieving precise subtype selectivity and navigating the structural complexity of this multi-pass membrane ion channel.
Key Mutations of CACNA1C
Based on public genomics databases (UniProt Q13936), the following variants are notable:
| Mutation / Variant | Associated Phenotype | Functional Effect |
|---|---|---|
| VAR_075148 (LQT8-related) | Long QT Syndrome 8; uncertain significance | Increased channel activity |
| VAR_044039 (BRGDA3-related) | Brugada Syndrome 3; uncertain significance | Affects channel activity |
| rs1051345 (dbSNP) | Population variant; no known disease association | Not characterized |
These variants underline the importance of assay systems capable of characterizing both loss- and gain-of-function mutations, especially for cardiac channelopathies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| State-Dependent Small Molecules | Pfizer, Biogen, SAGE Therapeutics, Zalicus, Novartis | Psychiatric Disorders, Refractory Pain, Arrhythmias | Use-Dependent Block Assay (requires stable excitable cell lines with CACNA1C + CACNB2) |
| Subunit-Selective Modulators | Academic Consortia, Structure-guided programs | Hypertension (Renal-selective), Arrhythmia | CACNA1C vs CACNA1D Selectivity Panel (Ortholog cell lines) |
| Gene Therapy / Editing | Timothy Syndrome Research Groups, Emerging Biotechs | Timothy Syndrome (G406R mutation) | Mutant CACNA1C Stable Cell Lines for validation; siRNA/ASO knockdown assays |
| Biologics (mAbs/scFv) | Early Stage Biotech | Cardiac Protection (Ischemia/Reperfusion), Refractory Hypertension | Extracellular Loop Binding & Functional Blockade Assays |
Summary of Differentiators
TarMart provides the complete toolkit for CACNA1C drug discovery:
- High-titer lentivirus for stable cell line generation with accessory subunits.
- Sequence-verified ORFs and mutant constructs (including Timothy Syndrome mutations).
- High-purity extracellular domain antigens for antibody development.
- Comprehensive panel of related targets (CACNA1D, CACNB2, CACNA2D1, RYR2) for selectivity and mechanism studies.